HRP20120969T1 - Spoj azola - Google Patents
Spoj azola Download PDFInfo
- Publication number
- HRP20120969T1 HRP20120969T1 HRP20120969AT HRP20120969T HRP20120969T1 HR P20120969 T1 HRP20120969 T1 HR P20120969T1 HR P20120969A T HRP20120969A T HR P20120969AT HR P20120969 T HRP20120969 T HR P20120969T HR P20120969 T1 HRP20120969 T1 HR P20120969T1
- Authority
- HR
- Croatia
- Prior art keywords
- carboxylate
- piperidine
- methylpyridin
- acceptable salt
- compound according
- Prior art date
Links
- -1 Azole compound Chemical class 0.000 title claims 12
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- OAQPDTFGBCUPKV-UHFFFAOYSA-N 4-[3-(2-fluorophenyl)-1H-1,2,4-triazol-5-yl]-2-(2-methylpyridin-3-yl)piperidine-1-carboxylic acid Chemical compound CC1=NC=CC=C1C1N(C(O)=O)CCC(C=2NN=C(N=2)C=2C(=CC=CC=2)F)C1 OAQPDTFGBCUPKV-UHFFFAOYSA-N 0.000 claims 2
- NOYXOORGOKRAAZ-UHFFFAOYSA-N 4-[5-(3-fluorophenyl)-1,3-oxazol-2-yl]-2-(2-methylpyridin-3-yl)piperidine-1-carboxylic acid Chemical compound CC1=NC=CC=C1C1N(C(O)=O)CCC(C=2OC(=CN=2)C=2C=C(F)C=CC=2)C1 NOYXOORGOKRAAZ-UHFFFAOYSA-N 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000012752 auxiliary agent Substances 0.000 claims 1
- HMOBXFQCFTZHPG-UHFFFAOYSA-N pyridin-3-yl 4-(3-phenyl-1h-1,2,4-triazol-5-yl)piperidine-1-carboxylate Chemical compound C1CC(C=2NN=C(N=2)C=2C=CC=CC=2)CCN1C(=O)OC1=CC=CN=C1 HMOBXFQCFTZHPG-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Spoj, naznačen time, da je odabran iz skupine koju čine:
piridin-3-il-4-(3-fenil-1H-1,2,4-triazol-5-il)piperidin-1-karboksilat,
6-metilpiridin-3-il-4-[3-(4-fluorofenil)-1H-1,2,4-triazol-5-il]piperidin-1-karboksilat,
6-metilpiridin-3-il-4-[5-(4-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat,
2,6-dimetilpiridin-3-il-4-[5-(3,4-difluorofenil)-1,2,4-oksadiazol-3-il]piperidin-1-karboksilat,
2-metilpiridin-3-il-4-[3-(2-fluorofenil)-1H-1,2,4-triazol-5-il]piperidin-1-karboksilat,
6-metilpiridin-3-il-4-(3-fenil-1H-pirazol-1-il)piperidin-1-karboksilat,
2-metilpiridin-3-il-4-[5-(3-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat, i
6-metilpiridin-3-il-4-[4-(4-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat,
ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljivo pomoćno sredstvo.
3. Uporaba spoja prema zahtjevu 1 ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje neuropatskih bolova.
4. Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u postupku liječenja neuropatskih bolova.
5. Spoj prema zahtjevu 1, naznačen time, da je to piridin-3-il-4-(3-fenil-1H-1,2,4-triazol-3-il)piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema zahtjevu 1, naznačen time, da je to 6-metilpiridin-3-il-4-[3-(4-fluorofenil)-1H-1,2,4-triazol-5-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema zahtjevu 1, naznačen time, da je to 6-metilpiridin-3-il-4-[5-(4-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema zahtjevu 1, naznačen time, da je to 2,6-dimetilpiridin-3-il-4-[5-(3,4-difluorofenil)-1,2,4-oksadiazol-3-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema zahtjevu 1, naznačen time, da je to 2-metilpiridin-3-il-4-[3-(2-fluorofenil)-1H-1,2,4-triazol-5-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
10. Spoj prema zahtjevu 1, naznačen time, da je to 6-metilpiridin-3-il-4-(3-fenil-1H-pirazol-1-il)piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
11. Spoj prema zahtjevu 1, naznačen time, da je to 2-metilpiridin-3-il-4-[5-(3-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
12. Spoj prema zahtjevu 1, naznačen time, da je to 6-metilpiridin-3-il-4-[4-(4-fluorofenil)-1,3-oksazol-2-il]piperidin-1-karboksilat ili njegova farmaceutski prihvatljiva sol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008182251 | 2008-07-14 | ||
| PCT/JP2009/062680 WO2010007966A1 (ja) | 2008-07-14 | 2009-07-13 | アゾール化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120969T1 true HRP20120969T1 (hr) | 2012-12-31 |
Family
ID=41550369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120969AT HRP20120969T1 (hr) | 2008-07-14 | 2012-11-28 | Spoj azola |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8207199B2 (hr) |
| EP (1) | EP2308869B1 (hr) |
| JP (1) | JP5423675B2 (hr) |
| KR (1) | KR101566051B1 (hr) |
| CN (1) | CN102099354B (hr) |
| AU (1) | AU2009273105B2 (hr) |
| BR (1) | BRPI0915876B1 (hr) |
| CA (1) | CA2730793C (hr) |
| CY (1) | CY1113439T1 (hr) |
| DK (1) | DK2308869T3 (hr) |
| ES (1) | ES2393245T3 (hr) |
| HR (1) | HRP20120969T1 (hr) |
| IL (1) | IL210226A (hr) |
| MX (1) | MX2011000415A (hr) |
| PL (1) | PL2308869T3 (hr) |
| PT (1) | PT2308869E (hr) |
| RU (1) | RU2493154C2 (hr) |
| SI (1) | SI2308869T1 (hr) |
| TW (1) | TWI434842B (hr) |
| WO (1) | WO2010007966A1 (hr) |
| ZA (1) | ZA201100139B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
| JP2013147430A (ja) * | 2010-04-28 | 2013-08-01 | Astellas Pharma Inc | 夜間頻尿の予防又は治療剤 |
| FR2974365B1 (fr) * | 2011-04-20 | 2017-08-25 | Centre Nat De La Rech Scient (C N R S) | 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques |
| DE102012018115A1 (de) | 2012-09-13 | 2014-03-13 | Matthias Lehr | Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase |
| US20150259344A1 (en) * | 2012-10-02 | 2015-09-17 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazole derivative |
| DE102013016573A1 (de) | 2013-10-04 | 2015-04-09 | Matthias Lehr | 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung |
| CN106632260B (zh) * | 2016-09-29 | 2019-04-26 | 上海天慈生物谷生物工程有限公司 | 一种小分子激酶抑制剂的制备方法 |
| CN117777121A (zh) * | 2016-10-24 | 2024-03-29 | 詹森药业有限公司 | 化合物及其用途 |
| EP3700934A4 (en) * | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
| CN107602550B (zh) * | 2017-10-25 | 2018-10-23 | 磐安县宸熙工艺品有限公司 | 一种脂肪酰胺水解酶抑制剂及其制备方法 |
| MA52365A (fr) | 2018-04-25 | 2021-03-03 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| CN108912112A (zh) * | 2018-08-14 | 2018-11-30 | 李敬敬 | 一种化合物、制备方法以及其在治疗疼痛中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ59398A3 (cs) * | 1996-06-29 | 1998-07-15 | Samjin Pharmaceutical Co., Ltd. | Piperazinové deriváty a způsob jejich přípravy |
| EP1458374A2 (en) | 2001-12-14 | 2004-09-22 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| AU2003210824A1 (en) | 2002-02-08 | 2003-09-02 | Bristol-Myers Squibb Company | (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| UA80841C2 (en) | 2002-10-07 | 2007-11-12 | Univ California | Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants) |
| FR2854633B1 (fr) * | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| FR2866884B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| PL2607362T3 (pl) * | 2005-02-17 | 2015-05-29 | Astellas Pharma Inc | Karboksylany piperydyny i piperazyny jako inhibitory FAAH |
| GB2424955B (en) | 2005-04-09 | 2008-07-16 | Siemens Ag | Flow meter with conductive coating |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| WO2007005510A1 (en) | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| JPWO2007020888A1 (ja) * | 2005-08-12 | 2009-02-26 | 武田薬品工業株式会社 | 脳・神経細胞保護剤および睡眠障害治療薬 |
-
2009
- 2009-07-10 TW TW098123505A patent/TWI434842B/zh not_active IP Right Cessation
- 2009-07-13 JP JP2010520857A patent/JP5423675B2/ja active Active
- 2009-07-13 KR KR1020117001096A patent/KR101566051B1/ko active IP Right Grant
- 2009-07-13 ES ES09797891T patent/ES2393245T3/es active Active
- 2009-07-13 RU RU2011105151/04A patent/RU2493154C2/ru active
- 2009-07-13 DK DK09797891.0T patent/DK2308869T3/da active
- 2009-07-13 PT PT97978910T patent/PT2308869E/pt unknown
- 2009-07-13 EP EP09797891A patent/EP2308869B1/en active Active
- 2009-07-13 MX MX2011000415A patent/MX2011000415A/es active IP Right Grant
- 2009-07-13 AU AU2009273105A patent/AU2009273105B2/en not_active Ceased
- 2009-07-13 SI SI200930389T patent/SI2308869T1/sl unknown
- 2009-07-13 CN CN2009801277856A patent/CN102099354B/zh active Active
- 2009-07-13 CA CA2730793A patent/CA2730793C/en not_active Expired - Fee Related
- 2009-07-13 US US13/054,057 patent/US8207199B2/en active Active
- 2009-07-13 BR BRPI0915876-6A patent/BRPI0915876B1/pt not_active IP Right Cessation
- 2009-07-13 WO PCT/JP2009/062680 patent/WO2010007966A1/ja active Application Filing
- 2009-07-13 PL PL09797891T patent/PL2308869T3/pl unknown
-
2010
- 2010-12-23 IL IL210226A patent/IL210226A/en not_active IP Right Cessation
-
2011
- 2011-01-05 ZA ZA2011/00139A patent/ZA201100139B/en unknown
-
2012
- 2012-11-28 HR HRP20120969AT patent/HRP20120969T1/hr unknown
- 2012-12-03 CY CY20121101178T patent/CY1113439T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011000415A (es) | 2011-03-15 |
| CA2730793A1 (en) | 2010-01-21 |
| KR20110038671A (ko) | 2011-04-14 |
| DK2308869T3 (da) | 2012-10-08 |
| RU2011105151A (ru) | 2012-08-20 |
| CN102099354A (zh) | 2011-06-15 |
| EP2308869A4 (en) | 2011-07-27 |
| RU2493154C2 (ru) | 2013-09-20 |
| JPWO2010007966A1 (ja) | 2012-01-05 |
| KR101566051B1 (ko) | 2015-11-04 |
| CY1113439T1 (el) | 2016-06-22 |
| EP2308869A1 (en) | 2011-04-13 |
| PT2308869E (pt) | 2012-12-06 |
| EP2308869B1 (en) | 2012-09-19 |
| AU2009273105B2 (en) | 2013-09-05 |
| US8207199B2 (en) | 2012-06-26 |
| BRPI0915876A2 (pt) | 2015-11-03 |
| JP5423675B2 (ja) | 2014-02-19 |
| CA2730793C (en) | 2014-12-30 |
| ES2393245T3 (es) | 2012-12-19 |
| ZA201100139B (en) | 2012-03-28 |
| BRPI0915876B1 (pt) | 2019-07-09 |
| PL2308869T3 (pl) | 2013-02-28 |
| US20110118311A1 (en) | 2011-05-19 |
| WO2010007966A1 (ja) | 2010-01-21 |
| IL210226A0 (en) | 2011-03-31 |
| AU2009273105A1 (en) | 2010-01-21 |
| CN102099354B (zh) | 2013-07-10 |
| IL210226A (en) | 2014-07-31 |
| TW201014840A (en) | 2010-04-16 |
| TWI434842B (zh) | 2014-04-21 |
| SI2308869T1 (sl) | 2012-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120969T1 (hr) | Spoj azola | |
| FI3362445T3 (fi) | Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus | |
| HRP20160421T1 (hr) | Derivat azola | |
| CL2013000884A1 (es) | El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer. | |
| RU2017114355A (ru) | Производные нафтиридина в качестве антагонистов альфа v бета 6 интегрина для лечения, в частности, фиброзных заболеваний | |
| NO20081434L (no) | 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser | |
| SI2947072T1 (sl) | 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni | |
| JP2006500348A5 (hr) | ||
| JP2004531473A5 (hr) | ||
| JP2011502958A5 (hr) | ||
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| RU2009111113A (ru) | Мидуляторы mglur5 | |
| MX2010004176A (es) | Derivado de triazol 1,3,5-trisustituido. | |
| JP2010505809A5 (hr) | ||
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
| ZA200903578B (en) | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | |
| NO20052803L (no) | Komplekser av e-2-metoksy-n-(3-{4-(3-metyl-pyridin-3-yloksy)-fenylam ino)-kinazolin-6-yl}-allyl)acetamid, deres fremstillingsmate og bruk | |
| EA201590687A1 (ru) | Лечение легкой и умеренной болезни альцгеймера | |
| JP2016525113A5 (hr) | ||
| IL239928B (en) | Preparations containing (s)-1-(4-(4-(4,3-dichlorophenyl(piperidino-(3-(2-(5-methyl4,3,1-oxodiazol-2-yl)-benzo[b]furan -4-yloxy-2-propanol for the treatment of depression | |
| JP2016520636A5 (hr) | ||
| HRP20171295T1 (hr) | Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc) | |
| EP4007575C0 (en) | 4-[5-[(RAC)-1-[5-(3-CHLORPHENYL)-3-ISOXAZOLYL]ETHOXY]-4-METHYL-4H-1,2,4-TRIAZOLE-3-YL]PYRIDINE FOR USE IN PREVENTING AND/OR TREATING STRESS | |
| UY31400A1 (es) | Composiciones farmaceuticas |